Adventures in Chromatography - Pharmaceutical Technology

Latest Issue
PharmTech

Latest Issue
PharmTech Europe

Adventures in Chromatography
Mistakes happen even in the best chromatography laboratories.


Pharmaceutical Technology

Someone peaked



"In our research lab, one person made fractions using column chromatography and the rest of us tested them in various assays," notes our GMP Agent-in-Place. "One particular fraction worked so well in one of our assays that the supervisor decided we should use it as a positive control in all of the assays.

"This worked fine until one day, the chromatographer was out of the lab. I went to his side of the bench and found the sample. When the assay was run, the result for the positive control was horrible! When the chromatographer came back, I told him what had happened.

"When he asked me which bottle I used, I replied, 'The one we always use.'

"That is when he walked me over to the bench and showed me two identical-looking bottles—one on one shelf, the other on a different shelf. When I pointed to the bottle that was used, he promptly told me, 'Oh, that's not the one I usually give you.'

"Both bottles were labeled exactly the same, except for recovery weight! The chromatographer explained that the chromatography peak that produced the sample was very large, and when dried it wouldn't all fit in one bottle. So one bottle contained the front half of the peak, while the second bottle contained the second half of the peak."

Wipe out!

"It was a standard industrial-scale chromatography purification station, with gleaming stainless steel and well-placed instrumentation," explains our GMP Agent-in-Place. "We really knew what we were doing—until we opened the column for a routine repacking.

"When the column was opened, there were a couple of durable laboratory wipes—you all know the ones I mean— laying on top of the resin! They could have been there for several column runs.

"Evidently, the wipes had been used to clean the bulk vessel and then were forgotten. Then, when the vessel was filled and the solution pumped through the connecting hose into the column, the wipes were pumped along for the ride. I started hating the word 'REJECTION.'"

Whodunit?

"I wish I knew who did it," gripes our GMP Agent-in-Place. "And even now, years later, we don't know whether it was a labeling mistake in the pharmacy department or an error in selecting the correct material in production. The result was that an incorrect salt compound was used to formulate the chromatography wash buffer.

"After loading the chromatography column, the misbegotten buffer was applied, and the product precipitated in the column. What a mess!

"Both the product and the column had to be rejected and destroyed—a half-million dollars down the tubes and no one to blame."

Pharmaceutical Technology's monthly "Agent-in-Place" column distills true-life cautionary tales from the secret files of Control, a senior compliance officer. If you have a story of clueless operators, oblivious management, inopportune lapses of judgment, or Murphy's Law in action, please send it to Control at
. We won't use any names, but if we do use your tale of disaster, courage, or just plain weirdness, Control will send you a coveted Pharmaceutical Technology t-shirt.

ADVERTISEMENT

blog comments powered by Disqus
LCGC E-mail Newsletters

Subscribe: Click to learn more about the newsletter
| Weekly
| Monthly
|Monthly
| Weekly

Survey
FDASIA was signed into law two years ago. Where has the most progress been made in implementation?
Reducing drug shortages
Breakthrough designations
Protecting the supply chain
Expedited reviews of drug submissions
More stakeholder involvement
Reducing drug shortages
29%
Breakthrough designations
10%
Protecting the supply chain
43%
Expedited reviews of drug submissions
10%
More stakeholder involvement
10%
View Results
Jim Miller Outsourcing Outlook Jim Miller Health Systems Raise the Bar on Reimbursing New Drugs
Cynthia Challener, PhD Ingredients Insider Cynthia ChallenerThe Mainstreaming of Continuous Flow API Synthesis
Jill Wechsler Regulatory Watch Jill Wechsler Industry Seeks Clearer Standards for Track and Trace
Siegfried Schmitt Ask the Expert Siegfried SchmittData Integrity
Sandoz Wins Biosimilar Filing Race
NIH Translational Research Partnership Yields Promising Therapy
Clusters set to benefit from improved funding climate but IP rights are even more critical
Supplier Audit Program Marks Progress
FDA, Drug Companies Struggle with Compassionate Use Requests
Source: Pharmaceutical Technology,
Click here